• Save
Quo Vadis EU Pharmacy?
Upcoming SlideShare
Loading in...5
×
 

Quo Vadis EU Pharmacy?

on

  • 4,639 views

PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com ...

PharmaCon2007 Congress, Dubrovnik, Croatia "New Technologies and Trends in Pharmacy, Pharmaceutical Industry and Education" http://www.pharmacon2007.com
Abstract is available at http://www.pharmaconnectme.com

Statistics

Views

Total Views
4,639
Views on SlideShare
4,625
Embed Views
14

Actions

Likes
2
Downloads
0
Comments
1

4 Embeds 14

http://www.slideshare.net 9
http://www.pharmaconnectme.com 3
http://cvformacio.ub.edu 1
http://preparaciondelamuestra.blogspot.com 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel

11 of 1

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
  • After you got all the information on Fioricet, another point on your agenda should be the price for it. http://www.fioricetsupply.com resolves this problem. Now you can make the decision to buy.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Quo Vadis EU Pharmacy? Quo Vadis EU Pharmacy? Presentation Transcript

  • Quo vadis EU Pharmacy? The Future of Pharmacy from an EU persepctive Ivana Silva Pharmaceutical & Professional Affairs PGEU
  • PGEU Introduction Austria Belgium Denmark Finland France Germany Greece Ireland Italy Luxembourg Portugal Spain Sweden The Netherlands United Kingdom Bulgaria Croatia Cyprus Czech Rep Hungary Latvia Malta Norway Poland Romania Slovakia Slovenia Switzerland Turkey Members: Professional Bodies & Pharmacists’ Associations 2007: 29 countries
  • Mission statement
    • " Community pharmacists in Europe are committed to making a major contribution to improving public health by:
      • seeking to ensure that people derive maximum therapeutic benefit from prescribed medication dispensed in pharmacies
      • providing high quality advice to ensure safe and responsible self-care including, where appropriate, self-medication
      • encouraging healthy lifestyles through effective health promotion and health education strategies”
  • Community Pharmacists
    • Are part of national health systems
    • Undertake activities which contribute to specific health policy objectives such as cost containment
    • Provide a range of services in the general interest of society
    (De)Regulation policy needs to fully take into account potential health impacts and public interest considerations
  • Community Pharmacists’ Added Value to the Health System
    • Health is wealth
      • Correct and rational use of medicines
      • Control and prevention of medication errors
      • Adherence to treatment
    • Additional services to society
      • Health and education campaigns
      • Prevention of drug misuse and abuse
      • Waste collection
    • Services for the Health System
      • Healthcare interventions by pharmacists
      • Facility of payments for the State
      • Generic substitution
      • Assistance in implementing national health policies
      • Data collection
    • 400.000 Community Pharmacists in Europe
    • 160.000 Community Pharmacies in Europe
    • 46 million citizens visit a pharmacy every day
    ~ 1300 2007
  • From product to patient = professional service
  • Community Pharmacy Services
    • Dispensing Prescriptions
    • Repeat Dispensing
    • Disposal of waste medicines
    • Provision of Emergency Contraception
    • Blood pressure measurement
    • Cholesterol measurement
    • Glucose measurement
    • Weight measurement
    • Pregnancy test
    • ...
    • Medicines Use Review
    • Smoking Cessation
    • Diabetes management
    • Asthma management
    • Hypertension management
    • Obesity management
    • Screening of high-risk cardiac patients
    • ...
    • Homecare services
    • Night services
    • ...
  • The Example of Dia betes Management
  • The example of high-risk cardiac patients
    • Collection of information on cardiovascular risk factors (e.g. hypertension, hyperlipidemia, diabetes)
    • Information on current list of prescription and non-prescription medications
    • Recommendations to the physician for optimizing vascular risk reduction therapies
    • Encouragement for patients to schedule appointments with their family physicians for further assessment
    • Follow-up of patients (including the introduction of a new risk reduction medication or dosage enhancement of an existing medication)
  • Community Pharmacy Services Determinants
    • Organisation of the health system
    • Legislation
    • Pharmacy dimension
    • Number of pharmacists/ pharmacy
    • Knowledge, experience and confidence
    • Competence, collaboration, competition and motivation
    STAKEHOLDER LEVEL GOVERNMENT & DR GROUP PROFESSIONAL LEVEL PROFESSIONAL ASSOCIATIONS COMMUNITY PHARMACY LEVEL SERVICE PROVISION IN PHARMACY CLINICAL ISSUES
  • IT use in Pharmacies
    • Pharmacist Information support
    • Pharmacist Decision support
    • Pharmacist Reporting
    • Patient records
    • Administrative processes
    • Orders management
    • Quality control
    • Electronic Communication and connectivity
  • 2007 Into the future
    • What do EU citizens and patients expect from healthcare?
    • How do EU policy-makers see healthcare?
    • How is the pharmacist activity perceived in the EU?
    • How can the EU dimension impact the daily practice of the Pharmacy Profession?
  • What do EU citizens and patients expect from healthcare?
    • Quality health services as near to their daily lives as possible;
    • Affordable healthcare;
    • To be healthy and stay healthy and active as long as possible;
    • Targeted treatment to their conditions, to their group age, to their specific needs;
    • To be empowered;
    • Access to innovative medicines;
    • Privacy;
    • Human and friendly healthcare settings;
    • To get well, not be harmed, and have the best possible quality of life.
  • How do EU policy-makers see healthcare? As a market As a cost As not their business As the infrastructure to ensure the universal right to health On a case by case political agenda topic
  • How is the pharmacist activity perceived in the EU?
    • By many, as
      • Money-makers, shop sellers, retailers
      • Not part of the discussion on health systems (seen as a private business sector)
      • Mistaken for pharmaceuticals
    • By a growing number, as
      • Healthcare professionals with an untapped potential in the EU healthcare workforce
      • Important to contribute to the achievement of health policy objectives (e.g. cost containment)
    • “ There is considerable scope to build on the current achievements in public health and pharmacists are probably the biggest untapped resource for health improvement”
    • A Vision for Pharmacy in the New NHS, July 2003
    • UK Health Department
  • Future Challenges: Resources for Health Financial Human Infrastructural Knowledge
  • How can the EU dimension impact the daily practice of the Pharmacy Profession? Regulatory Aspects Health Vs. Internal Market Professional Aspects
  • How can the EU dimension impact the daily practice of the Pharmacy Profession?
    • Liberalisation in Europe
    • Infringement Proceedings
    • Consultation on Health Services
    • Pharmaceutical Forum
    Regulatory Aspects
  • How can the EU dimension impact the daily practice of the Pharmacy Profession?
    • Reinforced EU Pharmacovigilance System
    • New/reviewed rules for information to Patients
    • Deployment of Electronic Health Records
    • New rules for Paediatric medicines and Advanced therapies
    • Control of pandemics
    • Implementation of Patient Safety strategies
    • Counterfeiting/ track and trace mechanisms
    Professional Aspects
  • How can the EU dimension impact the daily practice of the Pharmacy Profession?
    • Reinforced EU Pharmacovigilance System
    • New/reviewed rules for information to Patients
    • Deployment of Electronic Health Records
    • New rules for Paediatric medicines and Advanced therapies
    • Control of pandemics
    • Implementation of Patient Safety strategies
    Professional Aspects www.pgeu.eu
  • In conclusion…
    • Pharmacists need to continue:
      • to be proactive and dynamic;
      • abreast of developments;
      • to strengthen their competencies, covering skills, knowledge, behaviours and traits;
      • to demonstrate the added value of their daily community pharmacy practice to individual patients and society, to the Health System, to national Economy and to EU welfare.
  • Into the future
    • Pharmacists:
      • Through their national associations, will be ready to anticipate, face and influence discussions around the current organisation of the pharmacy sector in particular, and the healthcare sector in general;
      • Individually, on their daily practice, will be ready to help patients and citizens and contribute to their wellbeing and quality of life.
    • www.pgeu.eu
    • [email_address]
    Hvala lijepa!
  • Representing European Community Pharmacists